Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | RECQL | P46063 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 5/20 | 0.77 |
| ▸ | BLM | P54132 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
| ▸ | PKLR | P30613 | 2/20 | 0.77 |
| ▸ | GALNT2 | Q10471 | 2/20 | 0.77 |
| ▸ | APEX1 | P27695 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | CA12 | O43570 | 2/20 | 0.77 |
| ▸ | CA1 | P00915 | 2/20 | 0.77 |
| ▸ | CA7 | P43166 | 2/20 | 0.77 |
| ▸ | CA9 | Q16790 | 2/20 | 0.77 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ellagic Acid SCHEMBL9792365 | 0.97 | KDM4E (0.72) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL2168301 | 0.90 | KDM4E (0.77) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL1645767 | 0.88 | KDM4E (1.00) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL20429 | 0.88 | KDM4E (1.00) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL30475160 | 0.88 | KDM4E (1.00) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL29439360 | 0.88 | KDM4E (1.00) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL3800835 | 0.86 | KDM4E (0.70) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL9146254 | 0.86 | KDM4E (0.96) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL2639621 | 0.86 | KDM4E (0.96) | KDM4EMAPTMEN1KMT2ARECQL | |
| Ellagic Acid SCHEMBL8686557 | 0.86 | KDM4E (0.96) | KDM4EMAPTMEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382891-B2 | Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-07-12 | — | — | US | disclosed |
| US-20200222363-A1 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | Société des Produits Nestlé S.A. (CH) | 2020-07-16 | — | — | US | disclosed |
| EP-2897606-B1 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | NESTLE SA (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-10548873-B2 | Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2020-02-04 | — | — | US | disclosed |
| EP-2068864-B1 | THERAPEUTIC USES OF UROLITHINS | UNIV CALIFORNIA (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20150238461-A1 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | Société des Produits Nestlé S.A. (CH) | 2015-08-27 | — | — | US | disclosed |
| US-20150238462-A1 | COMPOSITION COMPRISING PLANT PHENOLS FOR PREVENTING OR REDUCING TEWL AND ASSOCIATED DISORDERS AND DISEASES | Société des Produits Nestlé S.A. (CH) | 2015-08-27 | — | — | US | disclosed |
| EP-2897605-A1 | COMPOSITION COMPRISING PLANT PHENOLS FOR PREVENTING OR REDUCING TEWL AND ASSOCIATED DISORDERS AND DISEASES | Nestec S.A. (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2897606-A1 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | Nestec S.A. (CH) | 2015-07-29 | — | — | EP | disclosed |
| CN-104619317-A | Composition comprising plant phenols for preventing or reducing tewl and associated disorders and diseases | NESTEC SA | 2015-05-13 | — | — | CN | disclosed |
| WO-2014044591-A1 | COMPOSITION COMPRISING PLANT PHENOLS FOR PREVENTING OR REDUCING TEWL AND ASSOCIATED DISORDERS AND DISEASES | NESTEC S.A. (CH) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014044836-A1 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | NESTEC S.A. (CH) | 2014-03-27 | — | — | WO | disclosed |
| US-8648112-B2 | Therapeutic uses of urolithins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-12-31 | — | — | US | disclosed |
| EP-2068864-A2 | THERAPEUTIC USES OF UROLITHINS | The Regents of the University of California (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1865942-A2 | NOVEL INHIBITORS OF GLUTATHIONE-S-TRANSFERASE | Universität Giessen (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007127263-A2 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006097472-A2 | NOVEL INHIBITORS OF GLUTATHIONE-S-TRANSFERASE | UNIVERSITÄT GIESSEN (DE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | UROD, UTS2R, PLAU | KDM4E 4122/4885MAPT 1484/4885MEN1 1034/4885 |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | UROD, UTS2R, PLAU | KDM4E 4122/4885MAPT 1484/4885MEN1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.